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ABSTRACT
Ischemia is a potentially fatal medical event that is associ-
ated with as many as 30% of all deaths. Stem cell therapy
offers signiﬁcant therapeutic promise, but poor survival fol-
lowing transplantation to ischemic tissue limits its efﬁcacy.
Here we demonstrate that nanosphere-mediated growth
factor delivery can enhance the survival of transplanted
human adipose-derived stromal cells (hADSCs) and secre-
tion of human angiogenic growth factors per cell, and sub-
stantially improve therapeutic efﬁcacy of hADSCs. In vitro,
in hypoxic (1% oxygen) and serum-deprived conditions that
simulate in vivo ischemia, ﬁbroblast growth factor-2 (FGF2)
signiﬁcantly reduced hADSC apoptosis and enhanced angio-
genic growth factor secretion. In vivo, hADSCs delivered
intramuscularly into ischemic hind limbs in combination
with FGF2 resulted in signiﬁcant improvements in limb sur-
vival and blood perfusion, as well as survival of the trans-
planted hADSCs and secretion of human angiogenic growth
factors (i.e., vascular endothelial growth factor, hepatocyte
growth factor, and FGF2). Interestingly, the majority of
transplanted hADSCs were localized adjacent to the micro-
vessels rather than being incorporated into them, suggesting
that their major contribution to angiogenesis might be to
increase paracrine secretion of angiogenic growth factors.
This study demonstrates the potential of hADSCs in com-
bination with growth factors for use in the treatment of
ischemia. STEM CELLS 2009;27:1976–1986
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INTRODUCTION
Adipose-derived stromal cells (ADSCs), multipotent stem
cells residing in the stromal-vascular fraction of adipose tis-
sues, are able to differentiate into multiple mesenchymal cell
types [1–3]. Several studies have demonstrated that stem cells
isolated from the stromal-vascular fraction of adipose tissue
can differentiate into endothelial cells, incorporate into ves-
sels, and promote postischemic neovascularization in vivo [4,
5]. Secretion of angiogenic and antiapoptotic factors such as
vascular endothelial growth factor (VEGF) and hepatocyte
growth factor (HGF) by ADSCs also enhances angiogenesis
in animal models of hind limb or myocardial ischemia [6–
10]. In addition, ADSCs are a favorable source of the large
number of cells required for transplantation because they can
be isolated from a small volume of adipose tissue or liposuc-
tion aspirates and expanded in vitro using standard cell cul-
ture technologies [11].
Despite the potential advantages of ADSCs, low therapeu-
tic efﬁcacy due to poor survival of cells transplanted into
ischemic tissues remains the largest obstacle to overcome in
stem cell therapy for angiogenesis. Cells transplanted into
ischemic regions are exposed to hypoxia immediately after
transplantation due to a lack of initial vasculature and are
prone to undergo apoptosis [12, 13]. Indeed, a high level of
cell death has been observed within a few days after trans-
plantation into ischemic muscles [14, 15]. The inﬂammatory
and proapoptotic environment in ischemic tissue also causes
poor survival of transplanted cells [16]. Thus, administration
of cells alone may not have a signiﬁcant enough effect on
angiogenesis induction.
To address these limitations, we investigated whether
nanosphere-mediated, local delivery of ﬁbroblast growth
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factor-2 (FGF2) could enhance the angiogenic efﬁcacy of
human ADSC (hADSC) therapy in treating mouse hind limb
ischemia. A delivery system based on biodegradable polymer
nanoparticles was used [17]. We previously demonstrated that
heparin-conjugated poly(L-lactide-co-glycolide) nanospheres
(HCPNs) suspended in ﬁbrin gel can locally release FGF2 for
up to 1 month [17]. One day after ischemia induction, athy-
mic mice received HCPN injection alone, hADSC transplant,
FGF2 delivery, or combined hADSC transplant and FGF2
delivery. The combination treatment of hADSC transplanta-
tion and FGF2 delivery led to a signiﬁcant improvement in
clinical markers including limb survival, angiogenesis, and
blood perfusion.
MATERIALS AND METHODS
An expanded Materials and Methods is provided in supporting
information.
Isolation and Culture of hADSCs
hADSCs were isolated and cultured as described previously [18].
Informed consent was obtained from all patients included in this
study according to approved procedures. Human lipoaspirates
were collected from patients by elective liposuction. Liposuction
tissue samples were washed extensively with phosphate-buffered
saline (Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com)
and digested at 37C for 30 minutes with 0.075% (wt/vol) colla-
genase type I (Sigma). After centrifugation at 1,200 rpm for
10 minutes, ﬂoating adipocytes were separated from the stromal-
vascular fraction. The isolated stromal-vascular fraction was incu-
bated overnight at 37C with 5% CO2 in an expansion medium
of Dulbecco’s modiﬁed Eagle’s medium (DMEM)/F-12 (Gibco-
BRL, Gaithersburg, MD, http://www.gibcobrl.com) supplemented
with 10% (vol/vol) fetal bovine serum (FBS; Gibco-BRL),
100 units/ml penicillin, and 100 lg/ml streptomycin. Following
incubation, tissue culture ﬂasks were washed to remove residual
nonadherent cells and maintained at 37C, 5% CO2 in expansion
medium. Cells were expanded for 7-10 days until they achieved
conﬂuence and were then subcultured. All experiments were
performed using the third passage of hADSCs.
hADSC Culture Under Hypoxic and
Serum-Deprived Conditions
When hADSC cultures reached 80% conﬂuence, the culture
medium (DMEM/F-12 medium with 10% FBS) was replaced
with fresh DMEM/F-12 without FBS. hADSCs were placed in
normoxic conditions (20% O2), hypoxic (1% O2) conditions, or
hypoxic conditions with daily addition of 50 ng/ml FGF2 for 2
and 4 days. At each time point, the cells in each group were
counted using a hemocytometer and conditioned medium was
collected for enzyme-linked immunosorbent assay (ELISA).
Mouse Hind Limb Ischemia
Hind limb ischemia was induced in mice as previously described
[19]. Four-week-old, female athymic mice (20 g body weight;
Jungang Lab Animal, Seoul, Korea, http://www.labanimal.co.kr/)
were anesthetized with xylazine (10 mg/kg) and ketamine (100
mg/kg). The femoral artery and its branches were ligated through
a skin incision using 5-0 silk suture (Ethicon, Somerville, NJ,
http://www.ethicon.com). The external iliac artery and all of the
above arteries were then ligated. The femoral artery was excised
from its proximal origin as a branch of the external iliac artery to
the distal point where it bifurcates into the saphenous and popli-
teal arteries. All animals received humane care in compliance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’
[20].
Treatment of Limb Ischemia
HCPNs were prepared and loaded with FGF2 as described previ-
ously [17]. One day after arterial dissection, the mice were
divided randomly into four experimental groups. The control
group received an injection of ﬁbrin gel (Greenplasts; Greencross
PD Co., Yongin, Korea, http://www.greencross.com/) with
HCPNs only (HCPN group, n ¼ 10). Fibrin gel plus HCPNs
loaded with 25 lg of FGF2 was injected intramuscularly into gra-
cilis muscle in the medial thigh (FGF2 group, n ¼ 10). hADSCs
(5.0  106 cells per mouse) were suspended in ﬁbrin gel with
HCPNs and injected intramuscularly without (hADSC group, n ¼
10) or with (hADSC þ FGF2 group, n ¼ 10) 25 lg of FGF2. To
identify the transplanted hADSCs, the cells were labeled with
enhanced green ﬂuorescence protein (eGFP) using a retroviral
vector prior to transplantation as described previously [21]. Physi-
ological status of ischemic limbs was followed up to 4 weeks af-
ter treatment.
Laser Doppler Imaging Analysis
Laser Doppler imaging analysis was performed as described pre-
viously [19]. A laser Doppler perfusion imager (Moor Instru-
ments, Devon, U.K., http://www.moor.co.uk) was used for serial
noninvasive physiological evaluation of neovascularization. Mice
were monitored by serial scanning of surface blood ﬂow in hind
limbs on days 0, 3, 14, and 28 after treatment. Digital color-
coded images were analyzed to quantify blood ﬂow in the region
from the knee joint to the toe and mean values of perfusion were
subsequently calculated.
Statistical Analysis
Quantitative data are expressed as mean  standard deviation.
Statistical analysis was performed by analysis of variance using a
Bonferroni test. A p value less than .05 was considered statisti-
cally signiﬁcant.
RESULTS
Inhibition of hADSC Apoptosis by FGF2 Under
Hypoxic and Serum-Deprived Conditions In Vitro
FGF2 improved hADSC proliferation and inhibited hADSC
apoptosis under hypoxic (1% oxygen) and serum-deprived
conditions that simulate in vivo ischemia [13]. Proliferation
of hADSCs cultured with daily addition of FGF2 to the cul-
ture medium for 2 and 4 days was signiﬁcantly higher than
that of hADSCs cultured without FGF2 (p < .05; Fig. 1A).
Mitochondrial metabolic activity and cell viability were also
signiﬁcantly enhanced (p < .05; Fig. 1B, 1C). Terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick-end
labeling (TUNEL) staining showed that hADSC apoptosis
was signiﬁcantly reduced at 2 and 4 days after culture under
hypoxic and serum-deprived conditions by daily FGF2 addi-
tion (p < .05; Fig. 2A, 2B). Daily addition of FGF2 reduced
p53 (proapoptotic factor) mRNA expression and enhanced
Bcl-xL (antiapoptotic factor) mRNA expression in hypoxic
hADSCs (Fig. 2C). When used in a 1-day hADSC culture
together with apoptosis-inducing factors, conditioned medium
from hypoxic hADSCs with FGF2 signiﬁcantly reduced
hADSC apoptosis compared with other conditioned media
(from hypoxic hADSCs without FGF2 and normoxic
hADSCs) and fresh medium (p < .05; Fig. 2D).
Enhancement of Angiogenic Factor Secretion
from hADSCs by FGF2 Under Hypoxic and
Serum-Deprived Conditions In Vitro
Addition of FGF2 to the culture medium promoted secretion of
angiogenic growth factors from hypoxic hADSCs. Reverse-
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transcription polymerase chain reaction (RT-PCR) showed that
VEGF mRNA expression in hADSCs was enhanced by hypoxia
(Fig. 3A). This result is consistent with a previous report that
hypoxia increases VEGF expression in hADSCs [6]. Daily
addition of FGF2 further increased VEGF mRNA expression in
hypoxic hADSCs (Fig. 3A). Exogenous FGF2 increased
Figure 1. Enhancement of hADSC proliferation and viability by FGF2 addition under hypoxic and serum-deprived conditions in vitro. hADSCs
were cultured for 2 and 4 days under normoxia (20% oxygen), hypoxia (1% oxygen), or hypoxia with daily FGF2 addition (50 ng/ml). (A): Number of
hADSCs counted using a hemocytometer. (B):Mitochondrial metabolic activity of hADSCs determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay. (C): Viability of hADSCs determined by neutral red assay. (#, p < .05, compared with hypoxia þ FGF2 daily addition
group and *, p< .05, compared with normoxia group). Abbreviations: FGF2, ﬁbroblast growth factor-2; hADSC, human adipose-derived stromal cell.
Figure 2. Inhibition of hADSC apoptosis by FGF2 addition under hypoxic and serum-deprived conditions in vitro. (A): TUNEL staining of
hADSCs 2 and 4 days after culture under normoxia (20% oxygen), hypoxia (1% oxygen), or hypoxia with daily FGF2 addition (50 ng/ml). Scale
bar indicates 100 lm. All photographs were taken at the same magniﬁcation. (B): Percentage ratio of TUNEL-positive cells (apoptotic cells) to
DAPI-positive cells (total cells) (#, p < .05, compared with hypoxia þ FGF2 daily addition group and *, p < .05, compared with normoxia
group). (C): Reverse-transcription polymerase chain reaction of hADSCs for proapoptotic (p53) and antiapoptotic (Bcl-xL) factors. (D): Percent-
age ratio of TUNEL-positive cells in hADSCs cultured with either fresh medium or various conditioned media 1 day after apoptosis induction.
Conditioned media were produced by culturing hADSCs under normoxia, hypoxia, or hypoxia with daily FGF2 addition (**, p < .05). Abbrevia-
tions: DAPI, 40,6-diamidino-2-phenylindole; FGF2, ﬁbroblast growth factor-2; hADSC, human adipose-derived stromal cell; TUNEL, terminal de-
oxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling.
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expression of endogenous FGF2 in hADSCs under hypoxic
condition (Fig. 3A). HGF mRNA expression was lower in
hypoxic hADSCs without FGF2 addition than in normoxic
hADSCs, but was signiﬁcantly enhanced in hypoxic hADSCs
by the presence of FGF2 (Fig. 3A). Quantiﬁcation of angio-
genic proteins using ELISA conﬁrmed that daily addition of
FGF2 signiﬁcantly increased secretion of angiogenic proteins
(Fig. 3B, HGF; Fig. 3C, VEGF) by hADSCs cultured under
hypoxic and serum-deprived conditions. Addition of FGF2 fur-
ther enhanced hypoxia-inducible factor (HIF)-1a expression
induced by hypoxia in hADSCs (supporting information
Fig. 1).
Improvement of Transplanted hADSC Survival by
Local Delivery of FGF2
Local delivery of FGF2 using HCPNs and ﬁbrin gel promoted
survival of hADSCs transplanted to ischemic regions of mouse
hind limbs. TUNEL staining of ischemic muscle retrieved 3
days after hADSC transplantation showed that the proportion of
TUNEL- and eGFP-positive hADSCs (apoptotic transplanted
hADSCs, arrows) was signiﬁcantly lower in the hADSC trans-
plantation group with FGF2 delivery (hADSC þ FGF2 group)
than in the hADSC transplantation alone group (hADSC group)
(p < .05; Fig. 4A, 4B). Human nuclear antigen (HNA)-positive
cells (transplanted hADSCs) were more abundant in the hADSC
þ FGF2 group compared with the hADSC group (p < .05; Fig.
4C, 4D). RT-PCR using human-speciﬁc primers showed that
local delivery of FGF2 enhanced mRNA expression of antiapop-
totic factor (Bcl-xL) in hADSCs transplanted into ischemic
regions while reducing proapoptotic factor (Bax) mRNA expres-
sion (Fig. 4E). Western blot for human HIF families (HIF-1a
and HIF-3a) revealed that local delivery of FGF2 also increased
the expression of HIF-1a and HIF-3a in hADSCs transplanted
into mouse ischemic tissue (supporting information Fig. 2).
Enhancement of Angiogenic Factor Secretion from
Transplanted hADSCs by Local Delivery of FGF2
Local delivery of FGF2 enhanced paracrine secretion of
angiogenic factors by hADSCs transplanted to ischemic sites.
Double immunoﬂuorescent staining for HNA and angiogenic
factors (VEGF, HGF, and FGF2) revealed that secretion of
these factors was higher in the hADSC þ FGF2 group than
the hADSC group (Fig. 5A–5C). RT-PCR using human-
speciﬁc primers conﬁrmed that human angiogenic factor
expression in ischemic muscles analyzed 3 days after hADSC
transplantation was enhanced by local delivery of FGF2 (Fig.
5D). Enhanced expression of paracrine angiogenic factors was
maintained for up to 28 days (Fig. 5E). This enhanced para-
crine action of hADSCs activated host (mouse) cells to pro-
duce higher level of angiogenic growth factors (VEGF and
FGF2) (supporting information Fig. 3). The expression of
mouse adhesion molecules (intercellular adhesion molecule-1
[ICAM-1] and platelet-endothelial cell adhesion molecule-1
[PECAM-1]) was increased in mouse ischemic tissue treated
with combined therapy of hADSC and FGF2, compared with
either single therapy alone (supporting information Fig. 4).
Enhancement of hADSC-Mediated Angiogenesis by
Local Delivery of FGF2
Local delivery of FGF2 and HCPNs to ischemic limb tis-
sues using ﬁbrin gel enhanced angiogenesis mediated by
hADSC transplantation. Immunoﬂuorescent staining for
mouse von Willebrand Factor (vWF) (Fig. 6A) and quanti-
ﬁcation of capillary density (Fig. 6C) revealed that the
combined therapy of hADSC transplantation and FGF2
delivery signiﬁcantly enhanced (p < .01) capillary forma-
tion (184  25/mm2) compared with HCPN implantation
(5  5/mm2) or single therapy (FGF2 delivery, 38  15/
mm2; hADSC transplantation, 69  13/mm2). Immunoﬂuo-
rescent staining for mouse smooth muscle (SM) a-actin
(Fig. 6B) and quantiﬁcation of arteriole density (Fig. 6D)
revealed that arteriole formation was signiﬁcantly enhanced
(p < .01) by the combined therapy (19  3/mm2) compared
with HCPN implantation (1  1/mm2) or single therapy
(FGF2 delivery, 2  1/mm2; hADSC transplantation, 8 
3/mm2). Many more HNA-positive hADSCs were detected
in the vicinity of capillaries and arterioles in ischemic tis-
sues from the hADSC þ FGF2 group compared with the
hADSC group (Fig. 6A, 6B). Most transplanted hADSCs
Figure 3. Enhancement of angiogenic factor secretion from human
adipose-derived stromal cells (hADSCs) by FGF2 addition under
hypoxic and serum-deprived conditions in vitro. (A): Reverse-tran-
scription polymerase chain reaction to examine angiogenic factor
expression in hADSCs 2 and 4 days after culture under normoxia
(20% oxygen), hypoxia (1% oxygen), and hypoxia with daily FGF2
addition (50 ng/ml). Cumulative release proﬁles of (B) HGF and (C)
VEGF from hADSCs at days 2 and 4, determined by enzyme-linked
immunosorbent assay. Daily addition of FGF2 to the culture medium
signiﬁcantly enhanced HGF and VEGF secretion from hADSCs under
hypoxia (#, p < .05, compared with hypoxia þ FGF2 daily addition
group and *, p < .05, compared with normoxia group). Abbrevia-
tions: FGF2, ﬁbroblast growth factor-2; HGF, hepatocyte growth fac-
tor; VEGF, vascular endothelial growth factor.
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were found adjacent to capillaries and arterioles in ische-
mic regions, although some hADSCs were incorporated
into mouse microvessels (arrows, small ﬁgures in Fig. 6A,
6B). RT-PCR analysis using mouse-speciﬁc primers indi-
cated that vWF and SM a-actin mRNA expression was
higher in the hADSC þ FGF2 group than in the other
groups (Fig. 6E). RT-PCR analysis using human-speciﬁc
primers showed that human vWF mRNA expression was
also higher in the hADSC þ FGF2 group than in the
hADSC group (Fig. 6F), suggesting that local delivery of
FGF2 promotes endothelial differentiation of hADSCs
transplanted to ischemic limbs. The expression of human
SM a-actin was detected in only combined therapy group
(hADSC þ FGF2) (supporting information Fig. 5).
Improvement of Ischemic Limb Salvage by hADSC Trans-
plantation with FGF2 Local Delivery. We investigated
whether the therapeutic potential of hADSC transplantation in
an athymic mouse model of hind limb ischemia could be
enhanced by local delivery of FGF2. After treatment, the con-
trol group (HCPN implantation) showed rapid and extensive
necrosis of the ischemic hind limbs, resulting in complete
limb loss via autoamputation by 28 days (Fig. 7A). All mice
receiving HCPN injection underwent limb loss (90%, 9 of 10)
or severe limb necrosis (10%, 1 of 10) without limb salvage
(0%, 0 of 10) (Fig. 7B). Single therapies (FGF2 delivery or
hADSC transplantation) slowed limb necrosis after treatment
(Fig. 7A), but more than 60% of the mice ultimately under-
went limb loss by 28 days (Fig. 7B). Intramuscular injection
of hADSCs with FGF2 signiﬁcantly reduced the rate of limb
loss compared with the other groups (Fig. 7A, 7B). Most
mice receiving the combined therapy exhibited limb salvage
(40%, 4 of 10) or mild limb necrosis (30%, 3 of 10), although
some lost limbs (30%, 3 of 10) (Fig. 7B).
Inhibition of Muscle Degeneration and Fibrosis in Ischemic
Limbs by Angiogenic Therapies. Histological examination
of ischemic limbs retrieved 28 days after treatment showed
Figure 4. Enhancement of transplanted hADSC survival by locally delivered FGF2 3 days after transplantation into ischemic limb muscle. (A):
TUNEL staining of hADSC and hADSC þ FGF2 groups. Prior to transplantation, hADSCs were labeled with eGFP gene (green) using a retrovi-
ral vector. Apoptotic nuclei were stained with rhodamine (red) by the TUNEL method. Apoptosis in transplanted hADSCs (arrows) was reduced
by FGF2 delivery. Scale bar ¼ 100 lm. Both photographs were taken at the same magniﬁcation. (B): The ratio of TUNEL- and eGFP-positive
cells (apoptotic transplanted hADSCs) to eGFP-positive cells (transplanted hADSCs) in ischemic regions (*, p < .05). (C): HNA staining of
hADSC and hADSC þ FGF2 groups. HNA-positive cells were more abundant in the hADSC þ FGF2 group than in the hADSC group. Scale
bar ¼ 100 lm. Both photographs were taken at the same magniﬁcation. (D): The ratio of HNA-positive cells (transplanted hADSCs) to DAPI-
positive cells (total cells) in ischemic regions (*, p < .05). (E): Reverse-transcription polymerase chain reaction for proapoptotic (Bax) and antia-
poptotic (Bcl-xL) factors in ischemic limb muscles retrieved at 3 days. Human-speciﬁc primers were used. Abbreviations: DAPI, 40,6-diamidino-
2-phenylindole; FGF2, ﬁbroblast growth factor-2; hADSC, human adipose-derived stromal cell; HCPN, heparin-conjugated poly(L-lactide-co-gly-
colide) nanosphere; HNA, human nuclear antigen; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling.
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that angiogenic therapies (hADSC transplantation, FGF2
delivery, or combined therapy) protected limb muscles from
necrotic damage by ischemia. Hematoxylin and eosin staining
of the control group (HCPN injection) showed massive mus-
cle degeneration in the ischemic regions and inﬁltration of
numerous granulocytes and neutrophils, indicative of tissue
inﬂammation after ischemia (Fig. 7C). In contrast, muscles in
the ischemic limbs of groups receiving angiogenic therapies
were protected from degeneration after treatment (Fig. 7C),
and Masson’s trichrome staining showed that ﬁbrosis was
markedly attenuated (Fig. 7D).
Improvement of Blood Perfusion in Ischemic
Limbs by hADSC Transplantation with Local
FGF2 Delivery
Laser Doppler perfusion imaging analysis (Fig. 7E) revealed
that blood perfusion in ischemic limbs was signiﬁcantly
improved in the hADSC þ FGF2 group compared with the
other groups. Fourteen days after treatment, the relative ratios
of blood ﬂow (ischemic to normal limb) were 46.9%  7.5%
in the hADSC þ FGF2 group and 11.5%  2.9% in the
HCPN group (p < .05; Fig. 7F). Perfusion in the FGF2 group
(19.5%  8.2%) and hADSC group (28.9%  8.3%) was sig-
niﬁcantly lower than in the hADSC þ FGF2 group (p < .05;
Fig. 7F). hADSC transplantation with FGF2 delivery signiﬁ-
cantly improved the relative ratio of blood perfusion (56.1%
 5.7%) compared with the other groups (HCPN injection,
14.8%  4.1%; FGF2 delivery, 26.3%  7.4%; and hADSC
transplantation, 36.3%  6.2%) 28 days after treatment (p <
.05; Fig. 7F).
DISCUSSION
Transplantation of ADSCs could be an alternative therapeutic
approach for treatment of ischemic heart and peripheral tissue
diseases. Although endothelial progenitor cells from periph-
eral blood [22, 23] or bone marrow [24, 25] have shown
angiogenic potential, these cell sources have limitations for
therapeutic angiogenesis. A large amount of autologous bone
marrow or peripheral blood is required to obtain a sufﬁcient
number of endothelial progenitor cells to induce satisfactory
reperfusion of ischemic tissues [26, 27]. This could cause
practical complications in some patients with severe cardio-
vascular disease such as myocardial infarction or atherosclero-
sis. In contrast, ADSCs can be easily isolated from a small
volume of adipose tissue harvested by a simple, minimally
invasive method and expanded in vitro to the numbers
required for transplantation [8, 11]. ADSCs can proliferate
rapidly and retain their mesenchymal pluripotency even after
long-term culture over several passages [8]. ADSC transplan-
tation can enhance angiogenesis in animal models of severe
hind limb or myocardial ischemia [8–10]. However, whether
Figure 5. Enhancement of angiogenic growth factor secretion from transplanted hADSCs by locally delivered FGF2. Double immunoﬂuorescent
staining for HNA and human-speciﬁc (A) VEGF, (B) HGF, and (C) FGF2 of ischemic hind limb muscle at 28 days. Signiﬁcant expression of
human angiogenic factors (green) was detected in the vicinity of hADSCs (pink) transplanted with FGF2 delivery compared with hADSCs trans-
planted without FGF2 delivery. Scale bar ¼ 100 lm. All photographs were taken at the same magniﬁcation. Reverse-transcription polymerase
chain reaction analysis of angiogenic growth factors using human-speciﬁc primers. Ischemic limbs were retrieved at (D) 3 days and (E) 28 days.
Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; FGF2, ﬁbroblast growth factor-2; hADSC, human adipose-derived stromal cell; HCPN, hep-
arin-conjugated poly(L-lactide-co-glycolide) nanosphere; HGF, hepatocyte growth factor; HNA, human nuclear antigen; TUNEL, terminal deoxy-
nucleotidyl transferase-mediated dUTP-biotin nick-end labeling; VEGF, vascular endothelial growth factor.
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Figure 6. Enhancement of hADSC-mediated angiogenesis by local FGF2 delivery in ischemic limbs 28 days after treatment. Double immuno-
ﬂuorescent staining for HNA and mouse-speciﬁc (A) vWF and (B) SM a-actin. Scale bars ¼ 100 lm. Quantiﬁcation of (C) capillary density and
(D) arteriole density in ischemic regions (*, p < .01, compared with hADSC þ FGF2 group and #, p < .05, compared with normal group). (E)
Reverse-transcription polymerase chain reaction (RT-PCR) analysis of vWF and SM a-actin using mouse-speciﬁc primers. (F) RT-PCR analysis
of CD31 and vWF using human-speciﬁc primers. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; FGF2, ﬁbroblast growth factor-2; hADSC,
human adipose-derived stromal cell; HCPN, heparin-conjugated poly(L-lactide-co-glycolide) nanosphere; HNA, human nuclear antigen; SM,
smooth muscle; vWF, von Willebrand factor.
Fig. 7
the major beneﬁts of ADSC therapy are due to direct vascular
differentiation of the ADSCs themselves or result from indi-
rect mechanisms such as paracrine support of ischemic tissues
remains controversial [4–10].
Local delivery of FGF2 enhanced the angiogenic efﬁcacy
of transplanted hADSCs, likely by enhancing their survival.
Our results showed that compared with either hADSC trans-
plantation or FGF2 delivery alone, hADSC transplantation
with local FGF2 delivery signiﬁcantly enhanced microvessel
formation and improved ischemic limb salvage and blood per-
fusion in ischemic limbs (Figs. 6, 7). It is well known that
poor viability of stem cells transplanted to ischemic sites lim-
its their therapeutic potential [14]. Importantly, our results
showed that FGF2 signiﬁcantly enhanced viability and prolif-
eration and reduced apoptosis of hADSCs cultured in vitro
under hypoxic conditions (Figs. 1A, 1C, 2). Similarly, local
delivery of FGF2 signiﬁcantly enhanced viability (Fig. 4C,
4D) and reduced apoptosis (Fig. 4A, 4B) of hADSCs trans-
planted to ischemic limbs. These results are consistent with
those of previous reports in which overexpression of FGF2
enhanced ADSC proliferation and improved the viability of
bone marrow-derived mesenchymal stem cells under hypoxic
conditions [28, 29]. FGF2 seems to improve cell survival by
activating several signaling components related to cell sur-
vival, including mitogen-activated protein kinase, Src, and
protein kinase C [30, 31], and by stimulating secretion of
antiapoptotic VEGF and HGF (Fig. 5E) [6].
Local delivery of FGF2 also enhanced the angiogenic efﬁ-
cacy of transplanted hADSCs, likely by enhancing paracrine
factor secretion. FGF2 signiﬁcantly enhanced the secretion of
HGF and VEGF by hADSCs cultured in vitro under hypoxic
conditions (Fig. 3). Following hADSC transplantation to is-
chemic limbs, local delivery of FGF2 also signiﬁcantly
enhanced mRNA expression of human HGF, FGF2, and
VEGF (Fig. 5D, 5E). Local delivery of FGF2 to ischemic
regions resulted in better hADSC survival and paracrine factor
secretion, probably through secretion of angiogenic growth
factors (Fig. 5A--5C), thus enhancing the therapeutic efﬁcacy
of hADSC transplantation. The enhanced paracrine action of
hADSCs activated host cells to produce higher level of angio-
genic growth factors (VEGF and FGF2) (supporting informa-
tion Fig. 3).
FGF2 could contribute to improvement of hADSC therapy
via the following potential signaling pathways. First, FGF2
might enhance the angiogenic efﬁcacy of hADSCs via activa-
tion of HIF families. Addition of FGF2 further enhanced HIF-
1a and HIF-3a expression induced by hypoxia in hADSCs
(supporting information Figs. 1, 2). This result is consistent
with the ﬁnding from a previous study showing that FGF2
enhances hypoxia-induced HIF-1a expression in many types
of cells [32]. Several studies have shown that HIF-1a activity
is essential for hypoxic induction of paracrine factor (VEGF,
FGF2, and HGF) expression and angiogenic signaling path-
way [33, 34]. Thus, exogenously added FGF2 might facilitate
secretion of paracrine factors from hADSCs by enhancing the
activity of HIF-1a. HIF-3a plays a role as a complement to
HIF-1a in protecting cells or tissues against hypoxic damage
[35]. Together these results (supporting information Figs. 1,
2) elucidate the relevance of HIF families to the action of
FGF2 on hADSC survival and paracrine secretion. Exogenous
FGF2 might enhance survival and paracrine action of
hADSCs by triggering intrinsic signaling pathway via HIF
families as well as directly affecting extrinsic pathway relat-
ing to cell proliferation. Second, adhesion molecules might be
involved in enhanced angiogenesis by hADSCs treated with
FGF2. The expression of adhesion molecules (ICAM-1 and
PECAM-1) was increased in mouse ischemic tissue receiving
combined therapy of hADSC and FGF2, compared with either
single therapy (supporting information Fig. 4). Enhanced
paracrine actions of hADSCs stimulated by FGF2 could acti-
vate host cells to express adhesion molecules [36]. The
increase in ICAM-1 and PECAM-1 expression on activated
host cells might promote the mobilization of endothelial pro-
genitor cells to ischemic sites and contribute to neovasculari-
zation [36]. This may explain another mode of enhanced para-
crine action of hADSCs by FGF2 delivery.
The present study shows that the paracrine effect of fac-
tors secreted by transplanted hADSCs, rather than differentia-
tion of hADSCs into vascular endothelial cells and direct par-
ticipation in vessel formation, may be its major contribution
to the repair of ischemic tissues. Some transplanted hADSCs
expressed endothelial or smooth muscle marker (Fig. 6F and
supporting information Fig. 5) and were incorporated into
vascular networks in ischemic sites, but the frequency was
quite low (small ﬁgures in Fig. 6A, 6B). Most hADSCs were
found in the vicinity of microvessels (Fig. 6A, 6B). Those
hADSCs might be present as pericyte-like cells in perivascu-
lar regions to support formation and stabilization of blood
vessels [37, 38]. Previous studies have also reported that vas-
cular differentiation of ADSCs transplanted into ischemic tis-
sues was rarely observed [8, 9]. Human angiogenic growth
factors (VEGF, HGF, and FGF2) were expressed in ischemic
limbs receiving hADSC transplant (Fig. 5). These results sug-
gest that transplanted hADSCs enhance angiogenesis through
secretion of human angiogenic growth factors. Interestingly,
treatment with small interfering RNA for HGF signiﬁcantly
inhibited ADSC-mediated angiogenesis [7], and treatment
with VEGF antibodies completely abolished mesenchymal
stem cell-mediated angiogenesis in ischemic tissues [39].
These ﬁndings suggest that ADSC transplantation could be
used in the context of cell-based cytokine therapy for thera-
peutic angiogenesis.
Physical incorporation and persistence of transplanted cells
are critical for neovascularization and functional tissue recov-
ery. A previous study has shown that deletion of transplanted
human cells via cell death induction at 1 or 2 weeks after
administration leads to a failure in improvement of neovascu-
larization and cardiac function in treating myocardial
Figure 7. Improvement of ischemic limb salvage by hADSC transplantation with local FGF2 delivery. (A) Representative photographs of
HCPN-, FGF2-, hADSC-, and hADSC þ FGF2-treated ischemic hind limbs on days 0, 3, 14, and 28 after treatment. (B) Physiological status of
ischemic limbs 28 days after treatment. hADSC transplantation with local FGF2 delivery signiﬁcantly improved the salvage of ischemic limbs
compared with the other treatments. (C) H&E staining (400) showed massive muscle degeneration in the ischemic regions of control limbs
(HCPN injection group). (D) Masson’s trichrome staining (400) showed that ﬁbrosis in the ischemic regions was markedly attenuated by
hADSC transplantation, local delivery of FGF2, and hADSC transplantation with FGF2 delivery. Scale bars ¼ 100 lm. All photographs were
taken at the same magniﬁcation. (E) Serial analysis of laser Doppler perfusion imaging performed 0, 3, 14, and 28 days after treatment. A greater
increase in blood perfusion was observed in ischemic limbs of mice receiving combined therapy compared with the other treatments (n ¼ 10 in
all groups). (F) Blood perfusion ratio of ischemic limbs measured by laser Doppler imaging 0, 3, 14, and 28 days after treatment. The ratio of is-
chemic to normal limb blood perfusion was signiﬁcantly improved by combined therapy at all time points (*, p < .05, compared with hADSC þ
FGF2 group). Abbreviations: FGF2, ﬁbroblast growth factor-2; hADSC, human adipose-derived stromal cell; HCPN, heparin-conjugated poly(L-
lactide-co-glycolide) nanosphere.
<
1984 Enhancement of ADSC Angiogenic Efﬁcacy Using FGF2
infarction [40]. Our staining data (Figs. 5A–5C, 6A, 6B)
revealed that a number of HNA-positive cells (transplanted
hADSCs) were present in ischemic regions 4 weeks after trans-
plantation. Although incorporation of hADSCs into vascular
networks is low, the persistence of hADSCs in perivascular sites
not only contributes to formation of blood vessels but also sta-
bilizes generated vascular networks in ischemic tissue through
extended paracrine secretion over 4 weeks. Our FGF2 delivery
system may increase the persistence of transplanted hADSCs
for long-term paracrine activities, resulting in improved angio-
genesis and functional recovery of ischemic limb.
The local delivery system composed of HCPN and ﬁbrin
hydrogel was designed to enhance the angiogenic efﬁcacy of
hADSC transplantation by controlling the delivery of growth
factor and cells. FGF2 can be released from HCPNs sus-
pended in ﬁbrin hydrogel at a controllable rate over 1 month
[17]. Long-term, local release of growth factor at a constant
rate can allow transplanted cells to be exposed to a steady
concentration over a long period [17]. Considering that most
angiogenic growth factors have a short half-life in vivo, con-
trolled and localized exposure to FGF2 could prolong survival
of transplanted cells and, in turn, improve the angiogenic efﬁ-
cacy of stem cell therapy for the treatment of ischemia. Deliv-
ery of cells to ischemic tissue using ﬁbrin hydrogel could
localize the transplanted cells in hydrogel matrix and maintain
their viability by separating them from the inﬂammatory and
proapoptotic environment [16]. In addition, cells in ﬁbrin ma-
trix may avoid anoikis or apoptosis following transplantation
through cell-matrix interactions, because ﬁbrin can provide
substrates that bind to cell adhesion receptors [41].
Our delivery system could be used for stem cell therapy
with other growth factors that have binding afﬁnity to heparin.
For example, VEGF-A, an important signaling protein enhanc-
ing cell proliferation and angiogenesis, has heparin binding
domains as FGF2 does [42], and thus could be loaded onto
HCPNs. VEGF-A delivery using HCPNs could improve the
therapeutic potential of hADSCs for ischemia treatment. Other
growth factors with binding afﬁnity to heparin (e.g., bone mor-
phogenetic protein [BMP]-2) can be also applied to promote
tissue regeneration of transplanted stem cells. It was reported
that ectopic bone formation of transplanted mesenchymal stem
cells is enhanced using HCPN-mediated BMP-2 delivery [43].
Several studies have demonstrated the beneﬁts of combin-
ing stem cell therapy and protein or gene therapy on the angio-
genic efﬁcacy of stem cell therapy. Local delivery of an appro-
priate growth factor to the transplantation site could allow
transplanted cells to adapt to in vivo hypoxic and inﬂammatory
microenvironments by stimulating signal pathways required
for cell survival, thus promoting their therapeutic efﬁcacy. The
present study shows that protein delivery can enhance the
angiogenic efﬁcacy of ADSC transplantation. Genetically
modiﬁed hADSCs may exhibit an enhanced therapeutic angio-
genesis via both autocrine and paracrine action. Previous stud-
ies have shown that genetic modiﬁcation of bone marrow mes-
enchymal stem cells with Akt or Bcl-2 genes improved their
therapeutic efﬁcacy in treating myocardial infarction through
enhanced paracrine effects (Akt [44, 45]) or reduced cell apo-
ptosis (Bcl-2 [46]). Combining bone marrow mononuclear cell
transplantation and in vivo angiopoietin-1 gene transfer pro-
moted functional neovascularization in hind limb ischemic tis-
sues [47]. However, most of studies have largely relied on viral
vectors to deliver those genes to stem cells, which are associ-
ated with signiﬁcant safety risks including immunogenicity,
mutagenesis, and possible toxicity [48]. Nonviral vectors that
can offer a safer delivery method still provide signiﬁcantly
lower delivery efﬁciency than viral vectors [49]. Therefore,
novel delivery systems ensuring both safety and efﬁciency
should be developed for genetic modiﬁcation to be another
strategy of enhancing the therapeutic efﬁcacy of stem cells.
SUMMARY
In summary, our study suggests that local delivery of FGF2
enhances the therapeutic angiogenic efﬁcacy of hADSC trans-
plantation through improvement of transplanted cell survival
and paracrine angiogenic factor secretion. The delivery sys-
tem used in this study could be applied to deliver dual or
multiple angiogenic factors that have afﬁnities for heparin,
such as VEGF and HGF [50], which could synergistically
enhance therapeutic angiogenesis using various types of stem
cells [51]. The local delivery system could also used be to
engineer large-volume tissues (e.g., bone, adipose, or skeletal
muscle) by facilitating angiogenesis.
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